








INVESTOR PRESENTATION | AUGUST 2010






MEDIGARD BACKGROUND

- Established as Medisafe Instruments Pty Ltd in 1999.
- The company was established to bring innovative, world-leading medical devices to the market via extensive research and development, with a focus on leading the way in safety equipment.
- Listed on ASX in 2004 as Medigard Limited (MGZ), raising \$3.4 million capital.






MEDIGARD TODAY

- Since 2004 Medigard has been designing and developing a suite of safety medical devices and associated products.
- Medigard's products transform the safety of disposable medical devices and associated equipment.
- Medigard is poised to enter international markets and become the industry standard.






MEDIGARD ACHIEVEMENTS

- FDA approval/US and Australian patent for the Blood Collection Device (BCD).
- US IP opinion on the BCD and Syringe validates design.
- Positive US product evaluations, 100% success.
- FDA application for Syringe imminent.
- US distribution and manufacturing agreements for BCD.






INGREDIENTS FOR SUCCESS

- Very large markets with significant growth rates
- Robust US healthcare sector underpinned by safety legislation
- Strong IP with positive US patent attorney opinions
- FDA approval Blood Collection Device, US granted patent
- Superior products in differentiated market segments
- Manufacturing and distribution partners supported by US hospital and pathology trials



MEDIGARD – THE NEXT PHASE

Transition Medigard from an R&D company to a market driven operating company offering innovative products that address critical safety needs of healthcare workers and their patients.



OVERVIEW

- Syringes:
 - Auto-retractable safety – 1mL, 3mL, 5mL, 10mL
 - Manual retractable safety – 3mL, 5mL, 10mL
- Blood Collection Device
- Intravenous Valve
- Flash Back Needle

BLOOD COLLECTION DEVICE

- Features inventive vacuum technology
- Prevents needle-stick injury with complete needle capture after use
- Unique design means a lower cost of production and competitive price
- Interchangeable needles and single-handed retraction



Extensive product testing has found that healthcare workers in the US and Australia unequivocally prefer Medigard's BCD to others.

RETRACTABLE SYRINGES

- Features complete needle retraction after use (auto and manual)
- Products include 1mL, 3mL, 5mL and 10mL
- No spring, Luer connection, interchangeable needles
- Minimises aerosoling



The Auto-retractable Syringe's vacuum mechanism is far less cumbersome than competitor's spring and sheath methods.

INTRAVENOUS VALVE

- Operates as an essential component of the cannula and as a stand-alone device
- Gives needle-less access and reduces the risk of needle-stick injury
- Two-way valve, clear visibility of fluids
- Design prevents backward flow and possibility of blood clotting



The Medigard IV valve design eliminates technology design faults that are common with other IV valve devices.




FLASH BACK NEEDLE

- Complementary product and attaches to the Blood Collection Device
- Observes immediate blood flash-back
- Allows healthcare workers immediate visual confirmation of a successful venipuncture






ABOUT THE MARKET




- Safety medical devices are key to reducing the incidence of needle-stick injuries and the subsequent spread of up to 20 blood-borne diseases including hepatitis B, hepatitis C and HIV/AIDS.
- The incidence of needle-stick injuries is on the rise with a 2005 study estimating the rate of injuries on a global level to affect about 3.5 million individuals.



ABOUT THE MARKET continued

- The US has introduced specific needle-stick prevention legislation.
- President Obama's healthcare bill adds 32 million people to the US healthcare system; increasing demand for such devices.





STRATEGIC PHASES




PHASE ONE → PHASE TWO → PHASE THREE → PHASE FOUR

R&D
Prototyping
Stages

Successful
Licensing
Product Sales
Agreements

Capital
Raising

Expansion and
more rapid
growth



PHASE ONE: R&D AND PROTOTYPING

COMPLETED

Safety (Auto-retractable) Syringes

Safety (Auto-retractable) BCD




Safety (Manual retractable) Syringes
(Prototypes successful)

R&D PHASE

Safety (Auto-retractable)
Pre-filled Syringes

Intravenous Valve

Flash Back Needle



PHASE TWO: SUCCESSFUL LICENSING/PRODUCT SALES AGREEMENTS

MARKETS




US, EU, UK, JAPAN, ASIA, OTHER

MANUFACTURING

Outsourced or OEM

STRATEGIC PARTNERS

Distribution and marketing
eg. agreements with US partners



PHASE THREE: CAPITAL RAISING

AUSTRALIAN CAPITAL MARKET

US CAPITAL MARKET




ALTERNATIVES

Rights Issue Prospectus

SPP

Private Placements



Private Placements




PHASE FOUR: EXPANSION AND GROWTH

Medigard - exclusive agreements with US manufacturer and distributor for its Blood Collection Device and has an estimated minimum income from these agreements.

The potential opportunities are outlined in the following slides.



BLOOD COLLECTION DEVICE FIVE-YEAR CASH FLOW



PROPOSED USE OF FUNDS 2011-2012




BCD Tooling for Production and Assembly	1,570,000
Syringe AR 3mL Tooling for Production and Assembly	1,750,000
Prototyping and R&D for the Company's suite of automatic retractable syringes, the Flash Back Needle and Intravenous Valve, product, testing and simulated clinical trials	330,000
Regulatory Compliance	100,000
Marketing Expenses	80,000

PROPOSED USE OF FUNDS 2011-2012





Patent Expenses	80,000
Working Capital	740,000
Capital Raising Expenses	150,000
TOTAL	\$4,800,000

WHY INVEST





- Investment in a large growing market.
- Unique, cost-effective, leading-edge products which respond to market demand.
- Penetration into the largest medical device market.
- Predicted strong future cash flow position.
- Dedicated Medigard team.



FUTURE MILESTONES – BCD



FUTURE MILESTONES – AR SYRINGE






MILESTONES AND COMMERCIALISATION

PRODUCT

5mL and 10mL Safety Retractable Syringes
 Prefilled Syringes
 Flash Back Needle
 1mL Safety Retractable Syringe
 Manual Retractable Syringes
 IV Valve

EXPECTED COMMERCIALISATION DATE

December 2011
 July 2012
 December 2011
 July 2012
 December 2012
 June 2013





CONTACT

Peter Emery | Chief Executive Officer
07 5528 0370 | 0412 258 027 | pemery@medigard.com.au

Peter Clark | Executive Director
07 5528 0370 | 0412 855 705 | pclark@medigard.com.au